# Bioresorbable Polymer-Coated EES in Patients at High Bleeding Risk Undergoing PCI Followed by 1-Month DAPT

Study · id `cardio:ct-nct03112707` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03112707](<https://clinicaltrials.gov/study/NCT03112707>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03112707

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1023 participants.

## Technical summary

Registry record NCT03112707. Allocation not applicable; no masking; primary purpose treatment. Start 2017-04-14 (actual); primary completion 2020-05-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1023 participants (planned count; ClinicalTrials.gov record NCT03112707, source copy `cardio:ctgov-nct03112707-2019-08-07`, retrieved 2026-10-26)
- Started: 2017-04-14 (actual) (ClinicalTrials.gov record NCT03112707, source copy `cardio:ctgov-nct03112707-2019-08-07`, retrieved 2026-10-26)
- Primary completion: 2020-05-01 (anticipated) (ClinicalTrials.gov record NCT03112707, source copy `cardio:ctgov-nct03112707-2019-08-07`, retrieved 2026-10-26)
- Completion: 2020-05-01 (anticipated) (ClinicalTrials.gov record NCT03112707, source copy `cardio:ctgov-nct03112707-2019-08-07`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT03112707, source copy `cardio:ctgov-nct03112707-2019-08-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03112707-2019-08-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Bioresorbable Polymer-Coated EES in Patients at High Bleeding Risk Undergoing PCI Followed by 1-Month DAPT
- Acronym: POEM
- Condition: Coronary Artery Disease
- Condition: Acute Coronary Syndrome
- Intervention (Drug): Aspirin
- Intervention (Drug): P2Y12 inhibitor
- Lead sponsor: Humanitas Hospital, Italy
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Early oral anticoagulation monotherapy after PCI: Insights from the POEM trial (`cardio:pubmed-41271123`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 861928fdd32f596bac3cde9da1ea1a5e5d766fa7b6f394192f632a91fb3c125b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
